News

Regeneron has signed two royalty agreements with Novartis that replaces previous collaboration and license agreement. Under the first royalty agreement, Regeneron is entitled to receive royalties on worldwide

For the quarter, the Company announced adjusted earnings per share of $0.03, compared with $0.08 in the corresponding period a year ago. Quarterly Highlights — Net revenue of

Xenon has announced a strategic alliance with Merck through an affiliate, to discover and develop novel small molecule candidates for the potential treatment of cardiovascular disease. In collaboration

Neurim has declared the preliminary results of phase-III study of Circadin 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. Circadinis, a

Neuromed has received notification that Merck will terminate the research collaboration and license agreement for novel compounds targeting N-type calcium channels, for the treatment of pain and other

New Jersey-based Wyeth has announced that the new data from phase-III clinical trials shows that investigational pneumococcal vaccine, Prevenar13, has the potential to provide coverage against the 13

Medivation has completed patient enrollment in the six-month, confirmatory, pivotal Phase-III trial of the investigational drug dimebon, in patients with mild-to-moderate Alzheimer’s disease. The pivotal Phase-III study enrolled

STAAR has announced that FDA has granted 510(k) clearance for Epiphany Injector System for use with the Affinity Collamer Three-Piece NTIOL and the Elastimide Silicone NTIOL. Epiphany has

Jubilant Organosys has announced that its Bangalore-based subsidiary, Jubilant Biosys has entered into a discovery and development collaboration with Endo Pharmaceuticals. Under the terms of the agreement, Jubilant